What the FDA labels say about taking them together
Cyclosporine and octreotide
Cyclosporine's FDA label of August 10, 2026 names octreotide in its drug interactions section, and octreotide's label names cyclosporine too. The octreotide label: “Cyclosporine: may have decreased bioavailability and require dose adjustment.”
Check it at the source: the cyclosporine FDA label on DailyMed (effective August 10, 2026, Novartis Pharmaceuticals Corporation); the octreotide FDA label on DailyMed (effective July 22, 2026, Novartis Pharmaceuticals Corporation).
What does the cyclosporine label say about octreotide?
Cyclosporine label, drug interactionsrifampin; oxcarbazepine; octreotide
Source: FDA drug label (Neoral), Novartis Pharmaceuticals Corporation, effective August 10, 2026 (SPL set 94461af3-11f1-4670-95d4-2965b9538ae3), via openFDA; the full label on DailyMed
What does the octreotide label say about cyclosporine?
Octreotide label, drug interactionsConcomitant administration of Sandostatin Injection with cyclosporine may decrease blood levels of cyclosporine and result in transplant rejection.
Mycapssa label (Chiesi USA, Inc., July 24, 2025), drug interactionsCyclosporine: may have decreased bioavailability and require dose adjustment ( 7 ).
Bynfezia Pen label (Sun Pharmaceutical Industries, Inc., February 21, 2025), drug interactionsDRUG INTERACTIONS The following drugs require monitoring and possible dose adjustment when used with BYNFEZIA PEN : cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine. (7) Lutetium Lu 177 Dotatate Injection:
Source: FDA drug label (Sandostatin Lar Depot, NDA021008), Novartis Pharmaceuticals Corporation, effective December 22, 2025 (SPL set d0b7fe9e-7000-4b79-ba3b-291ce92c14f9), via openFDA
Source: FDA drug label (Mycapssa, NDA208232), Chiesi USA, Inc., effective July 24, 2025 (SPL set 58d80bc6-bdfb-4908-93e7-aace447c8d1a), via openFDA
Source: FDA drug label (Bynfezia Pen, NDA213224), Sun Pharmaceutical Industries, Inc., effective February 21, 2025 (SPL set 20ed4e79-ad4c-426f-859d-83790c00439b), via openFDA
Source: FDA drug label (Sandostatin), Novartis Pharmaceuticals Corporation, effective July 22, 2026 (SPL set 4e2c9856-1836-49f0-9472-4dbeeb408f39), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cyclosporine | Octreotide | |
|---|---|---|
| Labeled for | Organ transplant rejection, Rheumatoid arthritis | Diarrhea |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $1.04 per unit 0.05% eye emulsion | $2.53 per mL 100 mcg/mL vial |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once